Scienture Holdings, Inc. (SCNX) Stock Price & Analysis
Scienture Holdings, Inc. (SCNX) fell 5.55% to USD 0.37 as of July 25, 2026 at 09:10 UTC, according to Nexqual real-time market data.
SCNX last closed at USD 0.39; the session ranged USD 0.37–0.39 on volume of 296,020 shares. Market capitalization is $15.00M, with a 52-week range of USD 0.24–2.6 (NCM). Source: Nexqual, July 25, 2026 at 09:10 UTC.
Key Statistics (as of July 25, 2026 at 09:10 UTC)
| Price | USD 0.37 |
|---|---|
| Change | ▼ 5.55% (down) |
| Previous Close | USD 0.39 |
| Open | USD 0.39 |
| Day Range | USD 0.37 – 0.39 |
| 52-Week Range | USD 0.24 – 2.6 |
| Volume | 296,020 shares |
| Market Cap | $15.00M |
| Exchange | NCM |
Technical Analysis (SCNX)
Nexqual's technical model rates SCNX "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 09:10 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 48.06 (neutral) |
| vs SMA50 | Below (USD 0.38) |
| MACD | 0.01 (positive) |
Analyst Ratings (SCNX)
Wall Street analysts rate SCNX "None" based on 1 analysts, with a mean price target of USD 1.5 (range USD 1.5–1.5), per Nexqual as of July 25, 2026 at 09:10 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 1.5 |
| High Target | USD 1.5 |
| Low Target | USD 1.5 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (SCNX)
| EPS Estimate | USD -0.09 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.08 vs est -0.22 ▲ beat |
| 2025-12-31 | USD -0.13 vs est -0.28 ▲ beat |
Source: Nexqual, July 25, 2026 at 09:10 UTC.
Financials & Fundamentals (SCNX)
| Total Revenue | $477,676 |
|---|---|
| Revenue Growth (YoY) | +449.10% |
| Gross Margin | +80.53% |
| Operating Margin | -6230.80% |
| Profit Margin | +0.00% |
| ROE | -56.56% |
| Debt / Equity | 0.02 |
| Current Ratio | 1.7 |
| Total Cash | $3.54M |
| Total Debt | $10,004 |
| Free Cash Flow | $-815,500 |
Source: Nexqual, July 25, 2026 at 09:10 UTC.
Financial Health Score (SCNX)
Nexqual rates Scienture Holdings, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 09:10 UTC.
| Growth | Strong — Revenue +449% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $4M cash, no debt |
| Cash Flow | Weak — FCF negative: -$816K, burning cash |
| Efficiency | Critical — ROE -57%, ROA -10.8% |
Ownership (SCNX)
| Insider Ownership | +13.31% |
|---|---|
| Institutional Ownership | +3.87% |
| Shares Outstanding | 40.63M |
| Float | 32.79M |
| Short % of Float | +6.87% |
Source: Nexqual, July 25, 2026 at 09:10 UTC.
Leadership (SCNX)
Scienture Holdings, Inc. is led by Shankar Hariharan (age 68), Founder, Co-CEO & Executive Chairman, per Nexqual as of July 25, 2026 at 09:10 UTC.
| Founder, Co-CEO & Executive Chairman | Shankar Hariharan (age 68) |
|---|---|
| President, Co-CEO, Interim CFO & Director | Narasimhan Mani (age 50) |
| Executive VP & COO of Scienture LLC | Rahul Surana |
Major Backers & Investors (SCNX)
Notable institutional backers of Scienture Holdings, Inc. include Fidelity, UBS Group AG, Virtu Financial LLC, according to Nexqual as of July 25, 2026 at 09:10 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.89% |
| UBS Group AG | 0.27% |
| Virtu Financial LLC | 0.21% |
| Xtx Topco Ltd | 0.12% |
| Commonwealth Equity Services, LLC | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.49% |
| Geode Capital | 1.06% |
Source: Nexqual, July 25, 2026 at 09:10 UTC.
From Scienture Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States.
- The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen.
- It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| WGRX | Wellgistics Health, Inc. | USD 3.52 | ▼ 1.68% |
| VSEE | VSee Health, Inc. | USD 0.08 | ▼ 1.25% |
| MSAI | MultiSensor AI Holdings, Inc. | USD 4.84 | ▼ 7.28% |
| XHLD | TEN Holdings, Inc. | USD 1.86 | ▼ 11% |
| YYAI | AiRWA Inc. | USD 11.33 | ▲ 38.18% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 09:10 UTC. This page is informational and not investment advice.